Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer

Jiajun Wu 1,†, Zuowei Xiao 1,†, Hongfang Li 1, Neng Zhu 2, Jia Gu 1, Wenmao Wang 3, Chao Liu 3, Wei Wang 4, and Li Qin 1,5,6,*

1 Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China; wujiajun10541@163.com (J.W.); 003831@hnucm.edu.cn (Z.X.); l15985025887@163.com (H.L.); gu583767721@163.com (J.G.)
2 Department of Urology, The First Hospital of Hunan University of Chinese Medicine, Changsha 410208, China; zhuneng10541@163.com
3 Zhangjiaju Meicha Technology Research Center, Hunan Qiankun Biotechnology Co., Ltd., Zhangjiaju 427000, China; 13907442657@163.com (W.W.; liuchao3333@icloud.com (C.L.)
4 TCM and Ethnomedicine Innovation & Development International Laboratory, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China; wangwei402@hotmail.com
5 Institutional Key Laboratory of Vascular Biology and Translational Medicine in Hunan Province, Hunan University of Chinese Medicine, Changsha 410208, China
6 Hunan Engineering Technology Research Center for Bioactive Substance Discovery of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China
* Correspondence: lqin@hnucm.edu.cn
† These authors contributed equally to this work.

Simple Summary: With the advancements in diagnosis and treatment technology, the mortality of patients with cancer is gradually decreasing. However, further curbing cancer development requires searching for innovative and more effective drugs. Natural herbal medicine has apparent advantages in R&D and healthcare costs and is attracting increasing attention. Dihydromyricetin is a flavonoid compound with a promising anticancer effect extracted from the stems and leaves of Ampelopsis grossedentata. This paper reviews the different mechanisms of dihydromyricetin alone or in combination with other drugs against a variety of cancers to provide a comprehensive reference for the development of dihydromyricetin as an anticancer therapeutic agent.

Abstract: Dihydromyricetin (DHM) is a natural flavonoid compound extracted from Ampelopsis grossedentata that has been used for centuries in traditional Chinese medicine. DHM has attracted intensive attention due to its numerous beneficial activities, such as hepatoprotection, cardioprotection, antioxidant, and anti-inflammation. In addition, DHM inhibits the progression of cancers such as lung cancer, hepatocellular cancer, breast cancer, melanoma, and malignant reproductive systems through multiple mechanisms, including antiangiogenesis, antiproliferation, apoptosis, and inhibition of invasion and migration. Notably, DHM also activates autophagy at different levels, exerting a dual-regulatory effect on cancers. Mechanistically, DHM can effectively regulate mammalian target of rapamycin (mTOR), noncoding RNA-mediated signaling, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, nuclear factor-κB (NF-κB), p53, and endoplasmic reticulum stress (ER stress)-driven signaling in different types of cancers. DHM has also been shown to have inhibitory effects on various regulators that trigger epithelial–mesenchymal transition (EMT). Furthermore, DHM exhibits a remarkable anticancer reversal ability when used in combination with drugs such as adriamycin, nedaplatin, and other drugs. However, the low bioavailability of DHM limits its potential applications, which are improved through structural modification and the exploration of novel dosage forms. Therefore, DHM may become a promising candidate for treating malignancies alone or combined with conventional anticancer strategies used in clinical practice.
Keywords: dihydromyricetin; anticancer activity; multidrug resistance

1. Introduction

Dihydromyricetin (3,5,7,3′,4′,5′-hexahydroxy-2,3-dihydroflavonol), known as ampelopsin, is a natural dihydroflavonol compound that was initially isolated from the stems and leaves of *Ampelopsis meliaeifolia* by Kotake and Kubota in 1940 [1]. They found that the content of DHM in *Ampelopsis grossedentata* was the highest, reaching more than 30% [2]. Moreover, DHM is also widely found in Myrica, Cuculidac, Clusiaceae, Euphorbiaceae, and other plants [3]. *Ampelopsis grossedentata* has long been utilized in traditional Chinese medicine. In the past, the Yao minority of Guangxi, Hunan, in China, made vine tea from its stems and leaves to alleviate cold and fever, sore throat, jaundice, hepatitis, and other symptoms, as well as prevent and treat nephritis, halitosis, and polyphagia [4].

DHM has multiple pharmacological effects, including anti-inflammatory, antioxidant, and hepatoprotective properties. At present, DHM prescription is recommended for treating various diseases, such as alcohol use disorders and metabolic or neurological imbalances [5]. DHM capsules have been marketed in the United States as a nutritional supplement to prevent alcohol hangovers [6]. Modern pharmacological studies have shown that DHM exhibits a significant inhibitory effect on liver cancer [7], lung cancer [8], breast cancer [9], and so on. Furthermore, DHM has an excellent synergistic effect combined with other anticancer drugs, with low cytotoxicity or adverse effects on normal cells or tissues. Acute/chronic toxicity experiments and genotoxicity experiments of DHM have shown that the toxicity of DHM is very weak. For example, the maximum tolerance in rats administered with DHM by gavage is 5.0 g/kg body weight [6]. These beneficial properties have made DHM a hotspot in the research and development of anticancer drugs in recent years.

2. Antioxidant and Anti-Inflammatory Activities of DHM

Cell metabolism produces reactive oxygen species (ROS), which act as intracellular signaling molecules [10], and a relative excess of ROS can cause oxidative stress [11]. Once antioxidant defenses are insufficient against oxidative stress, ROS may contribute to various diseases [12]. Thus, targeting antioxidant capacity may have beneficial therapeutic effects. A variety of polyphenolic compounds have been shown to possess potent antioxidant properties, enhancing the expressions of antioxidant enzymes through the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated pathways [13]. As a redox-sensitive transcription factor, Nrf2 plays a critical role in maintaining redox homeostasis by inducing the expression of antioxidant-related NADH quinone dehydrogenase 1 (NQO1), heme oxygenase-1 (HO-1), and other factors [14]. DHM can activate the Nrf2/Kelch-like ECH-associated protein-1 (Keap1) pathway, sequentially increasing the expression of NQO1 in HepG2 cells in a dose- and time-dependent manner, and exert antioxidant activity [15]. It also has a strong scavenging ability of 1,1-diphenyl-2-picrylhydrazyl free radical (DPPH) and oxygen radical absorbance capacity (ORAC) in vitro [15]. DHM has also been reported to activate the Nrf2/HO-1 pathway, upregulate antioxidant enzymes and antiapoptotic proteins, and protect human umbilical vein endothelial cells (HUVECs) from oxidative damage induced by oxidized low-density lipoprotein (ox-LDL) [16]. In in vivo studies, DHM administration significantly reduced oxidative stress induced by sleep deprivation (SD) in the brains of Institute of Cancer Research (ICR) mice; superoxide dismutase (SOD) activity was improved, and malondialdehyde (MDA) levels were decreased in the hippocampus of SD mice [17]. In a cisplatin-induced mouse kidney injury model, DHM reduced MDA level in mouse kidney tissue by attenuating cisplatin-induced oxidative and inflammatory stress, increasing catalase (CAT) and SOD activities, thus protecting them from nephrotoxicity damage [18].
Chronic inflammation caused by the interaction of myeloid-cell-derived ROS with tumor necrosis factor-alpha (TNF-α)-mediated signaling may contribute to cancer progression [19]. DHM attenuated the inflammatory responses by inhibiting the NF-κB pathway, especially the activity of fibroblast-like synovocytes (FLSs), in a rat model induced by interleukin-1β (IL-1β), thereby suppressing the proliferation, migration, and inflammatory responses of FLSs [20]. DHM can also inhibit doxorubicin-induced activation of the NLR family pyrin domain-containing 3 (NLRP3) inflammasome in H9C2 cells by blocking cysteinyl-aspartate-specific proteinase-1 (caspase-1) activity, suppressing IL-1β and IL-18 release, and upregulating sirtuin 1 (SIRT1) protein levels in vivo and in vitro [21]. In a mouse model of ovalbumin (OVA)-induced asthma, DHM reduced the number of inflammatory cells in bronchoalveolar lavage fluid and decreased the proinflammatory cytokine levels (such as IL-4, IL-5, IL-13) and secretion of ovalbumin-specific antibodies IgE and IgG1 in serum [22]. Furthermore, in a randomized, double-blind controlled clinical trial, DHM (150 mg capsules) twice daily for 12 weeks showed anti-inflammatory effects in patients with nonalcoholic fatty liver disease [23]. Oxidative stress and chronic inflammation are associated with the occurrence and development of diseases, especially cancers [24–26]. DHM has significant pharmacological effects in regulating inflammation and oxidative stress, which may be one of the reasons for the anticancer efficacy of DHM.

3. The Anticancer Potential and Underlying Mechanisms of Dihydromyricetin

3.1. Lung Cancer

According to the “latest Global Cancer Statistics 2020” released by the World Health Organization, lung cancer mortality has quadrupled over the past 40 years and has become the leading cause of cancer deaths in China (27.3%) [27]. Non-small-cell lung cancer (NSCLC) is a highly aggressive malignancy, accounting for more than 80% of total lung cancer patients. It is difficult to cure due to multidrug resistance and dose-dependent adverse reactions during the entire treatment process [28]. Studies have shown that DHM has anticancer activity against gefitinib-resistant and gefitinib-insensitive NSCLC cells, which causes apoptosis in NSCLC cell lines (A549 and H1975) by activating caspase-9/-7/-3 and cleaving poly ADP-ribose polymerase (PARP) [29]. However, it does not affect normal lung (WI-38) fibroblasts [29], indicating that DHM has fewer toxic side effects in anticancer therapy. Sustaining chronic proliferation during the cell cycle is the most fundamental trait of cancer cells [30]. Platelet-derived growth factors (PDGFs) have been shown to enhance the proliferation of fibroblast cells and extracellular matrix production [31], while interstitial fibroblasts can secrete various factors to increase the proliferative rate of cancer cells. It has been found that DHM can inhibit the PDGF-mediated proliferation of lung cancer fibroblasts by targeting the activation of the extracellular signal-regulated kinase (ERK1/2) and Akt pathways [32].

F-box proteins are an expanding family of eukaryotic proteins characterized by an “F-box” motif, which are responsible for substrate specificity in the ubiquitin–proteasome pathway, and play a pivotal role in programmed cell death [33]. F-box and WD repeat domain-containing 7 (FBW7) is a well-studied F-box-containing protein that functions as a cancer suppressor by targeting the oncoprotein substrate c-Myc for ubiquitination and degradation, thus regulating cell proliferation, apoptosis, and metabolism [34]. During DHM-induced apoptosis in A549 cells, the level of c-Myc protein levels and the expression of FBW7 were reduced in A549 cells [35], indicating that the ability of DHM to induce apoptosis is independent of FBW7. It is suggested that DHM can be used in drug-resistant cancers related to FBW7 deficiency.

3.2. Breast Cancer

Epidemiological studies have shown that the incidence of breast cancer increases rapidly during the reproductive years and gradually decreases around the age of 50 [36]. It has been proposed that treatment of breast cancer cell lines MCF-7 and MDA-MB-231 with DHM for 24 h results in a dose-dependent inhibition of cell viability in the above cell lines,
but there is no toxic effect on human normal breast epithelial MCF-10A cells [37]. DHM can inhibit mitochondrial oxidative phosphorylation (OXPHOS) and reduce adenosine triphosphate (ATP) production, leading to mitochondrial damage and causing accumulation of ROS, increased mitochondrial membrane permeability, and activation of Bcl-2-associated X protein (Bax), ultimately inducing apoptosis [38]. In addition, DHM-stimulated ROS accumulation also leads to an ER stress response, which in turn upregulates GRP78, p-PERK, and CHOP expression, thereby promoting apoptosis of breast cancer cells. Conversely, severe ER stress in turn promotes the production of ROS [37]. These results show that DHM-induced ROS generation and ER stress in breast cancer may generate a vicious loop that increases its inhibitory effect on cancer cells. Accumulating evidence has also demonstrated that DHM is involved in regulating Akt/mTOR-pathway–mediated autophagy in addition to apoptosis. Autophagy is a lysosomal-mediated degradation process of intracellular senescent proteins or damaged organelles [39]. Generally, upon autophagy affection, tumor cells show strong viability in harsh extracellular environments such as metabolic stress, hypoxia, nutrient deficiency, and anticancer therapy [40,41]. Experimental studies have shown that DHM promotes the conversion of microtubule-associated protein light-chain 3B-I (LC3B-I) to autophagosome-associated LC3B-II, downregulates the expression of p62, and induces autophagy to protect breast cancer cells from apoptosis through the ER-stress-mediated Akt/mTOR pathway [42]. These findings may contribute to the rationale for enhancing the efficacy of DHM against breast cancer by inhibiting protective autophagy.

3.3. Osteosarcoma

Osteosarcoma mainly occurs in the long bones of adolescents and children, including the humerus, ulna, radius, femur, fibula, and pelvis, and is the most common primary malignant bone cancer [43]. DHM protects osteosarcoma MG63 cells against oxidative-stress-induced apoptosis by downregulating caspase activation and upregulating B-cell lymphoma-2 (Bcl-2) [44]. It is known that the urokinase plasminogen activator (uPA) is a serine proteinase that increases the amount of plasmin generated by plasminogen, thereby disrupting the extracellular matrix (ECM) and promoting cancer invasion and migration [45]. DHM has been found to reduce the expression of transcriptional factors SP-1 and NF-κB from the cytoplasm to the nucleus via the ERK pathway, thereby reducing the ability of SP-1 and NF-κB to bind to the downstream uPA promoter, resulting in downregulation of uPA expression, and ultimately suppressing osteosarcoma metastasis [46]. Matrix metalloproteinases (MMPs) are members of a family of zinc-dependent proteolytic enzymes. The overexpression of MMP-2 and MMP-9 is associated with inflammation, tissue repair, and cancer progression metastasis [47]. DHM also blocks the migration and invasion of U2OS osteosarcoma cells by inhibiting MMP-2 expression stimulated by TNF-α [48]. Meanwhile, the G2/M-phase ratio is dramatically increased, which is related to the inactivation of GSK-3β in osteosarcoma cells with DHM treatment by stimulating 5′adenosine monophosphate-activated protein kinase α (AMPKα), resulting in upregulation of p21 expression and downregulation of Sox2 expression, thereby arresting the cell cycle [49].

3.4. Reproductive System Cancer

Ovarian cancer has one of the highest mortality rates among gynecological malignancies, with a high metastasis [50]. Notably, DHM can effectively inhibit the proliferation of ovarian cancer cells and induce cell apoptosis without apparent cytotoxicity to human ovarian surface epithelial cells [51]. EMT usually plays an important role in cancer progression, which refers to the fact that cells lose epithelial characteristics and acquire mesenchymal properties under special physiological or pathological conditions [52]. During ovarian cancer development, the occurrence of EMT can induce MMP production and accelerate the dissemination of cancer cells, thereby leading to the poor prognosis of ovarian cancer patients [53]. Moreover, DHM can block EMT via the NF-κB/Snail signaling pathway, upregulate E-cadherin expression, and downregulate the expressions of N-cadherin and vimentin in a concentration- and time-dependent manner, thus reducing the migration of
ovarian cancer [54]. DHM also impairs the motility and invasiveness of ovarian cancer SKOV3 and A2780 cells and stimulates the c-Jun N-terminal kinase (JNK)/ERK-caspase-3 pathway, leading to apoptosis by upregulating the cleaved caspase-3 and Bax/Bcl-2 ratio in ovarian cancer cells [55].

Choriocarcinoma is another malignant gynecological tumor of uterine origin that usually occurs after a hydatidiform mole, abortion, or full-term delivery. Since it is derived from placental trophoblasts, it is also called gestational trophoblastic cancer. Choriocarcinoma is currently considered the most aggressive type of trophoblastic tumor [56] and is particularly prone to early distant metastasis, resulting in a poor prognosis [57]. Studies have found that DHM can cause S/G2/M cycle arrest in human fetally derived trophoblast choriocarcinoma JAR cells by downregulating the expressions of cyclin A1, cyclin D1, Smad family member 3 (Smad3), and Smad4 [58]. In addition, DHM can also induce JAR cell apoptosis by increasing the Bax/Bcl-2 ratio and decreasing the expression of pro-caspase-3 [59].

Prostate cancer is the most common urinary system malignancy in men. DHM effectively suppresses the proliferation of prostate cancer cells by reducing angiogenesis and prevents in vitro migration and invasion of PC-3 human prostate cancer cell lines by downregulating the expression of C-X-C motif chemokine receptor 4 (CXCR4) [60]. However, the inhibitory effect of DHM on the proliferation of normal prostate epithelial cells is much lower than that of prostate cancer cell lines [60]. Taken together, DHM affects the progression of reproductive system malignancies by preventing EMT, delaying angiogenesis, triggering apoptosis, and arresting the cell cycle.

3.5. Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancer and is the most common pathological type. DHM can reduce Akt expression and increase p53 levels via the Akt/Bad signaling pathway, which in turn increases caspase-3 cleavage and its downstream target PARP, resulting in apoptosis of HepG2 cells [61,62]. In particular, DHM stimulates the p53 protein, thereby inhibiting the degradation of mouse double minute 2 homolog (MDM2), a negative regulator of p53 [63], and promoting the expression of the death receptors death receptor-4 (DR4) and death receptor-5 (DR5), which induces apoptosis in liver cancer hepatoma cells [64]. Notch1 is a multifunctional protein that performs a variety of key regulatory roles in cell differentiation, development, proliferation, and survival under variable conditions [65,66]. Its abnormal expression usually causes cancer. DHM can downregulate Notch1 expression and decrease the Bcl-2/Bax ratio in hepatoma cell lines QGY7701 and HepG2 in a time- and dose-dependent manner, inhibiting the proliferation of hepatoma cells [67]. DHM downregulates the expression of MMP-9 protein by increasing the level of protein kinase C-δ (PKC-δ) protein and inhibiting the phosphorylation of p38, ERK1/2, and JNK, which significantly suppresses the migration and invasion of human hepatoma SK-Hep-1 and MHCC97L cells [68].

Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is a key enzyme involved in ROS production [69]. It has been illustrated that DHM can downregulate the expressions of transforming growth factor β (TGF-β) and NOX4 in mouse hepatoma Hepal-6 cells, thereby reducing the production of ROS and ATP, inducing cancer cell apoptosis and avoiding damage to normal cells [70]. Although multiple pathways regulate the autophagy process in vivo, the mTOR signaling pathway is the most important. DHM induces autophagy by blocking the activation of mTOR at the stage of autophagosomes and acidic lysosomes, then impeding the proliferation of HepG2 cells [71].

3.6. Gastric Cancer and Cholangiocarcinoma

Gastric cancer is a malignant tumor originating from the gastric mucosa. Due to the lack of specificity and significance of early symptoms, more than 80% of gastric cancer patients in China are already in the advanced stage at the time of diagnosis, and combination therapy with fluorouracil and platinum is the first-line treatment for advanced gastric
However, its adverse effects are more prominent, and primary resistance or acquired resistance can ultimately lead to treatment failure and poor prognosis in patients with gastric cancer [73]. It has been found that DHM exerts anticancer effects by increasing the expression of p53 mRNA in a dose- and time-dependent manner and inhibiting Bcl-2 mRNA coding, as well as activating the endogenous mitochondrial pathway to induce apoptosis of AGS human gastric cancer cells [74]. DHM was also found to downregulate MMP-2 expression and inhibit the migration of human gastric cancer MKN45 cells through the JNK pathway [75]. High-motility group box 1 (HMGB1) plays a critical role in the enhancement of tumor angiogenesis and suppression of host anticancer immunity [76]. A study has shown that DHM reduces HMGB1 expression and suppresses the Akt/STAT3 pathways, thereby inhibiting the proliferation and migration of gastric cancer cells [77].

MicroRNAs (miRNAs) are small endogenous noncoding RNAs that play dual roles in cancer progression according to their targets. For example, microRNAs (miRNAs) located in amplified regions of the cancer genome (such as the miR-17-92 cluster) function as oncogenes, while miRNAs located in the deleted part of the cancer chromosome (such as the miR-15a-miR-16-1 cluster) have cancer-suppressing gene function [78,79]. Among them, miR-455 is a suppressor in various gastrointestinal cancers such as colorectal and pancreatic cancer [80,81], while miR-21 is an antiapoptotic and prosurvival factor [78]. DHM can enhance miR-455 expression, which decreases the expression of ZEB1, p-PI3K, and p-Akt in cholangiocarcinoma cell lines RBE and TFK-1 and suppresses cell proliferation and EMT in cholangiocarcinoma [82]. In addition, DHM also reduces the expression of miR-21, phosphorylated Akt, and MMP-9 and upregulates the expression of phosphatase and tensin homolog (PTEN) via the miR-21/PTEN/Akt pathway, attenuating the proliferation and invasion of human cholangiocarcinoma cells [83].

### 3.7. Colorectal Cancer

Colorectal cancer is a common malignant tumor of the digestive tract. Its early symptoms are usually not obvious, and 20–25% develop distant metastases at diagnosis [84]. The primary option for colorectal cancer treatment to prolong the survival of patients is chemotherapy intervention [85]. However, the efficacy of currently approved therapeutic drugs is quite limited, which can only increase survival for several months [86].

DHM can activate phosphorylation of AMPK and upregulate XIAP-associated factor 1 (XAF1) through ROS-mediated ER stress; subsequently, it upregulates XAF1 and disrupts mitochondrial membrane potential, leading to apoptotic death in colon cancer [87].

Studies have shown that inflammatory bowel disease is a significant risk factor for colon cancer [88–90]. DHM may fight against colon cancer by intervening in colitis-related factors. Butyrate, an important fiber metabolite in the gut, protects the host from colitis-associated colon cancer by enriching the genus prevotella. DHM has been found to delay colon cancer formation by maintaining lower butyrate levels during the hyperproliferative phase and by acting as an activator of chloride channels (CFTR, CLCN3, and CLCN4); 100 mg/kg DHM can also improve the dominant intestinal flora in high-fat-diet–fed cancer mice and reduce the susceptibility to colon cancers [91]. Human semaphorin 4D (Sema 4D) is highly expressed in a variety of aggressive cancers [92] and serves as a compensatory angiogenic factor to potentiate cancer growth and angiogenesis [93]. DHM has been demonstrated to significantly lower Sema4D expression in vivo and in vitro, resulting in a reduction in inflammatory invasion and limiting the expression of inflammatory factors and MDA levels in CoLo-205 colorectal cancer cells [94], reducing the risk of cancer development.

### 3.8. Melanoma

Malignant melanoma is the most aggressive and treatment-resistant form of skin cancer. Its aggressiveness is based on the highly metastatic potential of melanoma cells, even in the early stages [95]. DHM can affect melanoma initiation, invasion, and migration in multiple ways. DHM downregulates the expression of Cdc25A, Cdc2, and P-Cdc2,
blocking the cell cycle progression, resulting in a decrease in S-phase and G2/M-phase cells and a substantial increase in the proportion of G1-phase cells in SK-MEL-28 cells [96]. A previous study has also found that DHM induces apoptosis of SK-MEL-28 cells by increasing the Bax/Bcl-2 protein ratio and caspase-3 activity in a dose- and time-dependent manner [97]. Furthermore, DHM also rapidly activates autophagy through ROS-NF-κB signaling, which provides a cytoprotective mechanism for human melanoma cells and attenuates DHM-induced apoptosis [97]. In in vivo experiments, DHM can suppress the formation of lung metastases by blocking the invasion of B16 cells across the vascular subendothelial basement membrane, thereby inhibiting cell invasion and metastasis in a mouse model of B16 melanoma artificial lung metastasis [98]. In summary, inhibition of invasion and metastasis is the key step in melanoma therapy. However, the molecular targets of DHM are not yet precise and need further exploration.

3.9. Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is an aggressive, life-threatening disease that constitutes 90% of head and neck carcinomas (HNCs) [99], and DHM has good pharmacological activity against HNSCC. It has been demonstrated that DHM enhances p-STAT3-dependent autophagy by activating the ROS-signaling pathways, which provides a cytoprotective mechanism in HNSCC cells [100]. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is one of the highly conserved long noncoding RNAs, and its expression is closely related to the progression of malignant cutaneous cancer [101,102]. In cutaneous squamous cell carcinoma, DHM can inhibit the phosphorylation of malat1-transcription factor EB (TFEB), thereby activating TFEB nuclear translocation, increasing the activity of the TFEB reporter gene and the expression of autophagy-related genes and decreasing the expression of MALAT1, thereby disturbing MALAT1 homeostasis and promoting autophagic cell death in A431 cells [103]. DHM also has a certain anticancer effect on another common HNSCC, nasopharyngeal carcinoma (NPC). It is a nonlymphomatous squamous cell carcinoma derived from epithelial cells lining the nasopharynx [104]. DHM can silence the activation of p-IKKβ/α, block the nuclear translocation of NF-κB subunit p65, significantly suppress TNF-α-mediated NF-κB activation in CNE-2 cells, and reduce the expression levels of Bcl-2 and pro-caspase-3, resulting in CNE-2 cell apoptosis [105]. Moreover, DHM can inhibit the migration and invasion of NPC cells by suppressing the expression of MMP-2 by downregulating the ERK1/2 signaling pathway [106]. Figure 1 shows the anticancer mechanism of DHM.
Chemotherapy is one of the traditional strategies of cancer therapy. However, chemotherapy usually fails due to the drug resistance of cancer cells, of which multidrug resistance (MDR) is the most common. It refers to the cross-resistance of cancer cells to chemotherapeutic drugs with multiple structures and modes of action. Previous studies have shown that the expressions of the MDR gene (MDR1, MDR2), P-glycoprotein (P-gp) [107], and the multidrug-resistance-associated protein gene (MRP) [108] are closely related to MDR. Several studies have demonstrated that combining DHM with chemotherapeutic medicines may enhance chemosensitivity, reversing MDR (Figure 2). Adriamycin (ADR), a commonly used anthracycline chemotherapy drug, can cause fatal congestive heart failure due to its severe cardiotoxicity [109]. DHM promotes the accumulation of the antiapoptosis protein ARC (apoptosis repressor with caspase recruitment domain), prevents cardiomyocyte apoptosis, and has a synergistic anticancer impact in vitro and in vivo. The above effects are mainly achieved by modulating MDM2-mediated degradation of ARC ubiquitination [110]. This indicates that DHM is expected to become an effective cardioprotective agent against toxicity and increase the therapeutic window of ADR. Moreover, the combination of DHM and ondansetron (OND) suppresses soluble resistance-related calcium-binding protein (SORCIN) and thus impairs the function of the transporter P-gp, promoting the arrest of the G2/M phase and apoptosis induced by ADR and elevating the antiproliferation effect of ADR [111]. Furthermore, DHM also attenuates the drug efflux mediated by P-gp and then increases the intracellular accumulation of chemotherapeutic
drugs, thereby reversing the MDR of human leukemia K562/ADR cells [112]. In addition, DHM reverses the resistance to 5-FU in SGC7901/5-FU cells in a concentration-dependent manner by downregulating MDR1 mRNA expression and impeding the pumping effect of P-gp [113], indicating that DHM can be applied as an effective MDR reversal agent in the treatment of gastric cancer. It is known that the survivin gene is a member of the inhibitor of the apoptosis protein family, and the overexpression of survivin may provide growth and survival advantages for cancer initiation and progression [114]. DHM inhibits survivin expression and sensitizes ovarian cancer cells to paclitaxel and ADR dramatically, enhancing the effect of chemotherapy [51].

The combination of erlotinib (ELT) and DHM can increase the expression of Bcl-2-interacting mediator of cell death (Bim) and induce NOX2-ROS-dependent caspase apoptosis in erlotinib-resistant NSCLC cells through the NOX2-ROS-Bim pathway [115]. In addition, DHM also alters mitochondrial function by activating the p53/Bcl-2 pathway, promotes NDP-induced apoptosis of liver cancer cells, and reduces liver cancer cell damage by increasing the Bcl-2/Bax or Bcl-2/Bak ratio [116]. DHM also suppresses MRP2 transcription by blocking the Nrf2 pathway, reversing colorectal cancer cell resistance to oxaliplatin (OXA), and making colorectal cancer cells susceptible to OXA-induced death [117,118]. DHM promotes the anticancer effect of irinotecan (CPT-11) in colitis-related colon cancer and Min (APC min/+) mouse models [85]. The synergistic potential of DHM as an adjuvant to first-line anticancer drugs is gradually emerging. However, the low bioavailability of DHM still limits its activity. Therefore, DMH needs to be modified by medicinal chemistry to improve its efficacy in reversing drug resistance.

![Diagram of synergistic effects and mechanisms of DHM combined with different chemotherapeutic drugs](image-url)

**Figure 2.** Synergistic effects and mechanisms of DHM combined with different chemotherapeutic drugs. DHM is used in combination with a variety of drugs (such as ADR, OND, OXA, NDP, ELT, and PTX) to play a synergistic anticancer effect by increasing the sensitivity of cancer cells to drugs, reversing multidrug resistance, and inducing cancer cell death.

[Diagram showing DHM's interaction with various cancer drugs and pathways]
5. Challenges/Limitations

Despite the promising future of DHM in cancer therapy, its chemical instability and low bioavailability hinder its application. DHM is only soluble in hot water and ethanol and slightly soluble in water at 25 °C (200.3 µg/mL) [119]. For example, when rabbits were administered a dose of 115 mg/kg for 1.5 h, the plasma DHM concentration reached a maximum (159 µg/L), indicating a low bioavailability of DHM [120]. In addition, the phenolic hydroxyl structure of DHM makes it unstable. In particular, when DHM is exposed to light, pH buffers, pepsin, and trypsin, it will undergo various chemical reactions such as oxidation, hydrolysis, cleavage, and reduction, and decompose to produce metabolites [121]. Generally, DHM is stable in simulated gastric fluid and buffer solutions at pH 1.2 but undergoes pseudo-first-order kinetic degradation at pH 6.8 [122]. Pharmacokinetic studies have also shown that DHM is not easily absorbed into the blood and is unstable in the intestinal environment [123]. These results suggest that DHM may be metabolized and eliminated in the intestine. Therefore, gastrointestinal pH rather than digestive enzymes primarily affects the disintegration of DHM. DHM is slightly acidic due to the chemical structure of DHM containing many phenolic hydroxyl groups, which increases its stability under acidic conditions. Moreover, the transporters multidrug resistance protein 2 (MRP2) and breast cancer resistance protein (BCRP) inhibit DHM uptake and transport and block the absorption of DHM in the intestine [124].

DHM has regulatory effects on autophagy. It is known that autophagy can inhibit tumorigenesis by controlling the degradation of damaged components or proteins in cells [125]. Meanwhile, cancer cells can also utilize autophagy to adapt to various stresses, such as hypoxia or nutritional deficiency, to support the metabolism for tumor survival and excessive proliferation, and promote the growth of most advanced tumors [126]. There is currently a lack of adequate autophagy-based therapeutic interventions for cancer treatment. As previously described, DHM induces protective autophagy in breast cancer, melanoma, and HNSCC. On the contrary, DHM also prevents the occurrence and progression of hepatocellular carcinoma and cutaneous squamous cell carcinoma through autophagy. The stress-induced autophagy produced by DHM in different tumor cells exhibits multiple effects of anticancer therapy. Its specific effect may be related to different cancer types, stages of development, and genetic backgrounds [127]. Thus, an in-depth discussion of the unique roles of DHM-mediated autophagy in various types of malignancies in combination with tumor features is critical for rational selection of autophagy-targeted therapeutic options and eventual benefits.

Furthermore, a number of pathways have been revealed on how DHM regulates different cascades and inhibits/prevents cancer development. However, the precise targets of DHM signaling still need more exploration, and its pharmacological effects, distribution, and metabolic processes in animal models have not been comprehensively summarized. Evidence from clinical studies is also weak [23]. More in vivo studies through techniques such as multiomics are still required.

6. Strategies to Improve the Effects of DHM

6.1. Structural Modification

DHM has the disadvantages of low selectivity and weak pharmacological activity. Therefore, increasing the pharmacological activity and stability of DHM based on its structural characteristics and chemical modifications has potential prospects.

Generally, flavonoids can be acylated by using chemical or enzymatic methods. However, chemical acylation is not regioselective, which would lead to undesired functionalization of hydroxyl groups. In addition, enzymatic acylation is more regioselective and able to produce the desired acylation effect [128]. Previous studies have shown that regioselective enzymatic acylation of DHM with lipases from various sources can increase its solubility in lipid systems, with immobilized Penicillium expansum lipase and Novozyme 435 achieving the maximum conversion (85%) [129]. Furthermore, quantum chemical calculations have shown that the 3-OH of DHM has the lowest antioxidant activity, indicating that acylation
has the least influence on antioxidant activity at this position [129]. Recently, Cao et al. used the novel deep eutectic solvent (DES)-DMSO cosolvent system as the reaction medium and utilized immobilized lipase from Aspergillus niger (ANL) to catalyze the enzymatic acylation of DHM. The results revealed that DHM-16-acetate (91.6% conversion) was 10 times more lipophilic than DHM and exhibited good antioxidant activity [130]. Notably, studies have also demonstrated that proper acylation can enhance the lipophilicity, antioxidant activity, and thermal stability of DHM. However, excessive acylation of DHM reduces antioxidant activity and thermal stability [131]. Therefore, moderate acylation helps DHM to exert its antioxidant activity.

Glycosylation can significantly affect drug solubility, stability, bioavailability, and antioxidant properties [132,133]. Jin et al. synthesized five kinds of ampelopsis glycosides (AMPLS Gs) by the reaction of glucan sucrase with ampelopsin and sucrose receptor. Among them, the water-solubility, free-radical-scavenging, and antibrowning abilities of AMPLS-G1 were markedly improved [134], showing the whitening and moisturizing function of DHM glycosides playing in cosmetics.

The molecular structure of DHM has super delocalizability; a complete, conjugated, large π bond; strongly coordinating oxygen atoms; and a suitable spatial configuration, making it a good metal-ion-chelating ligand [135]. Three potential domains for binding metal ions exist in the DHM structure, including the 3,4′-dihydroxy group in the B ring and the 3-hydroxy or 5-hydroxy (in the A ring) and the 4-carbonyl groups in the C ring [136]. A previous study has demonstrated the interactions between bovine serum albumin (BSA) and DHM-Cu(II), DHM-Mn(II), and DHM-Zn(II) complexes. Different DHM-metal complexes can alter the transportation, disposition, and pharmacological effects of free DHM [137].

6.2. Drug Delivery Systems

Carrying traditional drugs through nanomaterials (micelles, liposomes, nanoparticles, etc.) can improve drug solubility, prolong drug half-life in vivo, and enhance bioavailability [138]. For example, DHM-loaded Solutol® HS15 micelles (DHM-Ms) prepared by the thin-film hydration method have better sustained-release properties than free DHM. In the single-pass intestinal perfusion model, the absorption rate constant (Ka) and permeability coefficient (Papp) of DHM-Ms are 5.5 and 3.0 times higher than those of pure DHM, respectively. The relative bioavailability of DHM-Ms (AUC0–∞) is 205% compared to free DHM (AUC0–∞), significantly increasing the bioavailability of DHM [139]. On the other hand, PE-Gylated dihydromyricetin-loaded liposome-encapsulated tea saponin grafted on chitosan (TS/CTS@DHM-Lips) as an effective cationic antibacterial agent, exhibiting good water solubility and aqueous solution stability capable of controlled release of DHM in weakly acidic and neutral physiological environments [140]. In addition, DHM-encapsulated zein caseinate nanoparticles (DZP) can be prepared by using zein nanoparticles as carriers to enhance the biostability of DHM. Data from UPLC-QqQ-MS/MS quantity analysis have demonstrated that the bioavailability of DHM in rats is increased by 1.95 times, and the concentration of its metabolites in rat plasma is also elevated, suggesting that the nanoparticles significantly improve the adhesion of DHM in the gastrointestinal tract of mice [141], which may facilitate the absorption of DHM by prolonging its residence time in the upper gastrointestinal tract [142].

Drug–drug cocrystals consisting of two or more active pharmaceutical ingredients (APIs) have been developed as a new class of solid-form APIs [143,144]. Studies have shown that the drug–drug (1:1) cocrystal hydrate of DHM and pentoxifylline (PTY) prepared by the slimy method achieves the simultaneous sustained release of DHM and PTY and has a synergistic anticancer effect on HepG2 cells in vitro at a concentration of 100 µM [145]. In addition, the DHM-loaded gastric-floating sustained-release tablet (DHM-GFT) is prepared by direct powder compression, and pharmacokinetic studies have shown that DHM-GFT has a good intragastric floating ability and sustained-release effect in an acidic environment,
which could significantly prolong the retention time of drugs in the body and improve bioavailability [146].

7. Conclusions and Perspectives

Dihydromyricetin, a natural flavonoid with various beneficial biological activities, has significantly progressed in its role and mechanism in cancer prevention research (Table 1). DHM inhibits cancer development through antiangiogenesis, antiproliferation, apoptosis, and suppression of invasion and migration. In particular, DHM has a prominent effect in synergistic anticancer with traditional chemotherapeutic drugs, which can effectively reverse drug resistance and avoid severe adverse reactions. Although DHM has shown to have a therapeutic effect on certain cancers in vivo and in vitro studies, its molecular mechanism remains unclear, particularly DHM-activated autophagy’s different roles in various cancers. Most studies on DHM focus on the cellular level, involving signaling pathways such as Akt/mTOR, NF-κB, and p53, and the target of direct antitumor function is still unknown. In particular, in clinical trials, no substantial progress has been made. A disadvantage of DHM is its relative lack of potency, requiring micromolar concentrations of the drug to be effective, limiting progress in vivo and clinical studies. In addition, due to factors such as low solubility, DHM also suffers from poor bioavailability, which limits its pharmacological effects and clinical applications. To date, the bioavailability and activity of DHM have been enhanced by chemical modification and the development of novel drug delivery systems such as nanocapsules and self-assembled micelles. Taken together, DHM is a potential anticancer Chinese medicine monomer, which is worthy of in-depth study and development in the future.

### Table 1. Anticancer activities of dihydromyricetin.

| Cancer Type               | Cell Types (Animals) | Concentration of DHM | Upregulated Related Proteins                        | Downregulated Related Proteins | Effect of DHM                        | Ref |
|--------------------------|----------------------|----------------------|-----------------------------------------------------|---------------------------------|-------------------------------------|-----|
| Lung cancer              | A549, H1975          | 75 µM                | Caspase-9/-7/-3; JNK1/2; ERK1/2                     | PARP; Bcl-w                     | Apoptosis                           | [29]|
|                          |                      | 30 µM                | XIAP; survivin; HDAC2; c-Myc; Skp2; FBW7α; FBW7γ; GSK-3β | Apoptosis proliferation inhibition | [35] |
|                          |                      | 10 µM                | ERK1/2; Akt                                        | Proliferation inhibition        | [32] |
| HepG2                    |                      | 50 µM                | Beclin-1; LC3-II; PI3K; AMPK; p-ERK1/2; p-Akt; PDK1 | Invasion inhibition             | [71] |
|                          |                      | 30 µM                | Bax; caspase-3                                     | Bcl-2                           | Apoptosis                           | [61]|
|                          |                      | 100 µg/mL            | caspase-3/-9/-8; DR4; DR5; Bax; p53                | Bcl-2                           | Apoptosis                           | [64]|
| Hepatocellular carcinoma| HepG2, Hep3B         | 200 µM               | p-Chk1; p-Chk2; CDK1                                | Cycle arrest                     | [7]  |
|                          | HepG2, QGY7701, Hepal-6 | 100 µM            | p53; caspase-3                                     | Bcl-2                           | Apoptosis                           | [62]|
|                          | QGY7701, HepG2       | 100 µM               | Bax                                               | Notch1; Hes1; Bcl 2             | Apoptosis                           | [67]|
Table 1. Cont.

| Cancer Type                        | Cell Types (Animals) | Concentration of DHM | Upregulated Related Proteins | Downregulated Related Proteins | Effect of DHM | Ref |
|------------------------------------|----------------------|----------------------|------------------------------|--------------------------------|---------------|-----|
| Hepatocellular carcinoma           | Hepal-6              | 100 µM               |                              | TGF-β; TGF-βRII; Smad; p-Smad2/3; NOX4; ROS; ATP | Apoptosis     | [70]|
|                                    | SK-Hep-1, MHCC97L    | 50–100 µM            | PKC-δ                        | MMP-9; P-ERK1/2; JNK            | Invasion inhibition | [68]|
|                                    | HepG2, HL7702        | 50 µM                | caspase-9/8/-3; HO-1; BAK     | ROS; GSH; ATP; Bcl-2            | Apoptosis     | [147]|
| Cholangiocarcinoma                 | HCCC9810, TFK-1      | 156.8 µM             | Caspase-3; Bad; PTEN          | p-Akt; Bcl-2; MMP9; vimentin; miR-21 | Invasion inhibition | [83]|
| Colon cancer                       | Colo-205 (male Balb/c nude mice) | 64 Mm (100 mg/kg)       | GSH; CAT; SOD; GPX; HO-1     | Sema4D; ROS; MDA; COX-2; iNOS | Proliferation inhibition | [94]|
|                                    | HCT-116, HCT-8, HT-29 | 100 µM               | GRP78; CHOP; p-AMPK; XAF1    | p-p38; p-JNK; Bcl-2; Mcl-1     | Apoptosis     | [87]|
| Gastric cancer                     | AGS                  | 25–100 µM            | p53 mRNA                      | Bcl-2 mRNA                    | Apoptosis     | [74]|
|                                    | BGC-823              | 80 µg/mL             |                               | HMGB1                         | Proliferation inhibition | [77]|
| Breast cancer                      | MCF-7, MDA-MB-231    | 80 µM                | ROS; GRP78; p-PERK; CHOP     | p-Akt; p-mTOR; p-p70S6K          | Apoptosis     | [37]|
|                                    |                      | 60 µM                | p-eIF2α; cleaved ATF6α       |                                 | Autophagy     | [42]|
| Human melanoma                     | SK-MEL-28            | 100 µM               | Caspase-3; ROS; LC3; p62; Beclin-1 |                                 | Apoptosis     | [97]|
|                                    |                      | 100 µM               | p53; p21                      | Cdc25A; Cdc2; P-Cdc2            | Cycle arrest  | [96]|
| Human ovarian cancer               | A2780                | 50 µM                | E-cadherin; p65              | N-cadherin; vimentin; Snail    | Invasion inhibition | [54]|
|                                    | SKOV3, A2780         | 120, 80 µM           | caspase-3; Bax                | Bcl-2; GRASP65                 | Apoptosis     | [55]|
| Prostate cancer                    | LNCaP, PC-3 (male severe combined immune-deficient mice) | 25 µM, 60 µM (300 mg/kg) |                              | CDK2; Cdc2; Bcl-2; CXCR4       | Invasion inhibition | [60]|

Cancers 2022, 14, 3487
Cancers 2022, 14, 3487

Table 1. Cont.

| Cancer Type                      | Cell Types (Animals)                      | Concentration of DHM | Upregulated Related Proteins | Downregulated Related Proteins | Effect of DHM          | Ref  |
|----------------------------------|------------------------------------------|----------------------|-----------------------------|-------------------------------|------------------------|------|
| Choriocarcinoma                  | JAR                                      | 100 mg/L             | Smad3; p-Smad3; Smad4; cyclin A1; cyclinD1 | Proliferation inhibition     | [58]       |
|                                  |                                          | 100 mg/L             | caspase-3; Bax; Bcl-2        | Apoptosis                     | [59]       |
| Osteosarcoma cells               | U2OS, MG63, Saos2, HOS, 143B cells (athymic nude (nu/nu) mice) | 30 µM (300 mg/kg)    | p21; AMPKα; p38MAPK; GSK-3β; JNK | Sox2                          | Proliferation inhibition [49] |
|                                  |                                          |                      |                             |                               | [46]       |
|                                  | U-2OS, HOS                               | 100 µM               | IkBα                        | SP-1; NF-κB; uPA, ERK2        | Invasion inhibition    | [46] |
|                                  | U2OS, MG63, HOS                          | 60 µM                | p21; AMPKα                   | GSK-3β; Sox2                  | Invasion inhibition    | [48] |
| Nasopharyngeal carcinoma         | CNE-2                                    | 160 µg/mL            | p-IKKβ; p-IKKα               | Bcl-2; pro-caspase-3          | Apoptosis              | [105]|
|                                  | HONE-1, NPC-BM, NPC-39                   | 100 µM               | ERK1/2; MMP-2                |                               | Invasion inhibition    | [106]|

Author Contributions: All authors contributed to the development of this review article. Critical analysis and review of the literature were performed by J.W. and Z.X. The manuscript was written by J.W. and Z.X., with revisions provided by H.L., N.Z., J.G., W.W. (Wenmao Wang), C.L. and W.W. (Wei Wang). The manuscript was guided by L.Q. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Sciences Foundation of China (No. 81973668, 81774130), the Key Project of the Educational Department of Hunan Province (No. 20A375), the Scientific Research Project of Changsha Science and Technology Bureau (No. kz2004060), the Key Project of Hunan Provincial Health Commission (202213055529), the First-Class Discipline of Pharmaceutical Science of Hunan, and the Special Scientific and Technological Project for the Comprehensive Utilization of Ampelopsis grossedentata Resources of Hunan Qiankun Biotechnology Co., Ltd.

Conflicts of Interest: The authors declare that they have no conflicts of interest.

References
1. Kou, X.; Chen, N. Pharmacological potential of ampelopsin in Rattan tea. Food Sci. Hum. Wellness 2012, 1, 14–18. [CrossRef]
2. Guo, L.; Zhang, H.; Yan, X. Protective effect of dihydromyricetin revents fatty liver through nuclear factor-κB/p53/B-cell lymphoma 2-associated X protein signaling pathways in a rat model. Mol. Med. Rep. 2019, 19, 1638–1644. [CrossRef] [PubMed]
3. Wang, H.; Li, Q. Application research and development of dihydromyricetin. Jiangsu Condiment Subsid. Food 2018, 4, 1–5. [CrossRef]
4. Murakami, T.; Miyakoshi, M.; Araho, D.; Mizutani, K.; Kambara, T.; Ikeda, T.; Chou, W.H.; Inukai, M.; Takenaka, A.; Igarashi, K. Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin. BioFactors 2004, 21, 175–178. [CrossRef]
5. Li, H.; Li, Q.; Liu, Z.; Yang, K.; Chen, Z.; Cheng, Q.; Wu, L. The Versatile Effects of Dihydmoyricetin in Health. Evid. Based Complement. Altern. Med. 2017, 2017, 1053617. [CrossRef]
6. Liu, D.; Mao, Y.; Ding, L.; Zeng, X.A. Dihydmoyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability. Trends Food Sci. Technol. 2019, 91, 586–597. [CrossRef]
7. Huang, H.; Hu, M.; Zhao, R.; Li, P.; Li, M. Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway. Oncol. Rep. 2013, 30, 2467–2475. [CrossRef]

8. Jiang, J.F.; Zhai, J.; Liu, Z.R.; Zhao, Y.F.; Wu, Y.J.; Cui, M.X. Ampelopsin sodium induces mitochondrial-mediated apoptosis in human lung adenocarcinoma SPC-A-1 cell line. Die Pharm. 2016, 71, 455–459. [CrossRef]

9. Huang, C.; Huang, Y.L.; Wang, C.C.; Fan, Y.L.; Lai, Y.H.; Huang, H.C. Ampelopsins A and C Induce Apoptosis and Metastasis through Downregulating AxL, TYR3, and FYN Expressions in MDA-MB-231 Breast Cancer Cells. J. Agric. Food Chem. 2019, 67, 2818–2830. [CrossRef]

10. Hayes, J.D.; Dinkova-Kostova, A.T.; Tew, K.D. Oxidative Stress in Cancer. Cancer Cell 2020, 38, 167–197. [CrossRef]

11. Sies, H. Oxidative stress: A concept in redox biology and medicine. Redox Biol. 2015, 4, 180–183. [CrossRef] [PubMed]

12. Gill, J.G.; Piskounova, E.; Morrison, S.J. Cancer, Oxidative Stress, and Metastasis. Cold Spring Harb. Symp. Quant. Biol. 2016, 81, 163–175. [CrossRef] [PubMed]

13. Tanigawa, S.; Fujii, M.; Hou, D.X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med. 2007, 42, 1690–1703. [CrossRef] [PubMed]

14. Tebay, L.E.; Robertson, H.; Durant, S.T.; Vitale, S.R.; Penning, T.M.; Dinkova-Kostova, A.T.; Hayes, J.D. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic. Biol. Med. 2015, 85, 108–116. [CrossRef] [PubMed]

15. Xie, K.; He, X.; Chen, K.; Chen, J.; Sakao, K.; Hou, D.X. Antioxidant Properties of a Traditional Vine Tea, Ampelopsis grossedentata. Antioxidants 2019, 8, 295. [CrossRef]

16. Luo, Y.; Lu, S.; Dong, X.; Xu, L.; Sun, G.; Sun, X. Dihydromyricetin protects human umbilical vein endothelial cells from injury through ERK and Akt mediated Nrf2/HO-1 signaling pathway. Apoptosis Int. J. Program. Cell Death 2017, 22, 1013–1024. [CrossRef]

17. Li, H.; Yu, F.; Sun, X.; Xu, L.; Miu, J.; Xiao, P. Dihydromyricetin ameliorates memory impairment induced by acute sleep deprivation. Eur. J. Pharmacol. 2019, 853, 220–228. [CrossRef] [PubMed]

18. Wu, F.; Li, Y.; Song, H.; Zhang, Y.; Zhang, Y.; Jiang, M.; Wang, F.; Mu, Q.; Zhang, W.; Li, W.; Li, L.; et al. Preventive Effect of Dihydromyricetin against Cisplatin-Induced Nephrotoxicity In Vitro and In Vivo. Evid. Based Complement. Altern. Med. 2016, 2016, 7937385. [CrossRef]

19. Canli, Ö.; Nicolas, A.M.; Gupta, J.; Finkelmeier, F.; Goncharova, O.; Pesic, M.; Neumann, T.; Horst, D.; Löwer, M.; Sahin, U.; et al. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. Cancer Cell 2017, 32, 869–883.e5. [CrossRef]

20. Wu, J.; Zhao, F.T.; Fan, K.J.; Zhang, J.; Xu, B.X.; Wang, Q.S.; Tang, T.T.; Wang, T.Y. Dihydromyricetin Inhibits Inflammation of Fibroblast-Like Synoviocytes through Regulation of Nuclear Factor-xB Signaling in Rats with Collagen-Induced Arthritis. J. Pharmacol. Exp. Ther. 2019, 368, 218–228. [CrossRef]

21. Sun, Z.; Lu, W.; Lin, N.; Lin, H.; Zhang, J.; Ni, T.; Meng, L.; Zhang, C.; Guo, H. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. Biochem. Pharmacol. 2020, 175, 113888. [CrossRef] [PubMed]

22. Qiu, P.; Dong, Y.; Li, B.; Kang, X.J.; Gu, C.; Zhu, T.; Luo, Y.Y.; Pang, M.X.; Du, W.F.; Ge, W.H. Dihydromyricetin modulates p62 and autophagy crosstalk with the Keap-1/Nrf2 pathway to alleviate ethanol-induced hepatic injury. Toxicol. Lett. 2017, 274, 31–41. [CrossRef] [PubMed]

23. Chen, S.; Zhao, X.; Wan, J.; Ran, L.; Qin, Y.; Wang, X.; Gao, Y.; Shu, F.; Zhang, Y.; Liu, P.; et al. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacol. Res. 2015, 99, 74–81. [CrossRef]

24. Chen, K.; Zhang, J.; Beeraka, N.M.; Tang, C.; Babayeva, Y.V.; Sinelnikov, M.Y.; Zhang, Y.; Liu, J.; Reshetov, I.V.; et al. Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers. Front. Oncol. 2022, 12, 820968. [CrossRef]

25. Chen, K.; Lu, P.; Beeraka, N.M.; Sukoecheva, O.A.; Madhunapantula, S.V.; Liu, J.; Sinelnikov, M.Y.; Nikolenko, V.N.; Bulgin, K.V.; Mikhailova, L.M.; et al. Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers. Semin. Cancer Biol. 2022, 83, 556–569. [CrossRef]

26. Garo, L.P.; Ajay, A.K.; Fujivara, M.; Gabriely, G.; Raheja, R.; Kuhn, C.; Kenyon, B.; Skillin, N.; Kadowaki-Saga, R.; Saxena, S.; et al. MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat. Commun. 2021, 12, 2419. [CrossRef]

27. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]

28. Bareschino, M.A.; Schettino, C.; Rossi, A.; Maione, P.; Sacco, P.C.; Zeppa, R.; Gridelli, C. Treatment of advanced non small cell lung cancer. Environ. Toxicol. 2017, 32, 1426–1438. [CrossRef]

29. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]

30. Heldin, C.H.; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999, 79, 1283–1316. [CrossRef]

31. Fan, K.J.; Yang, B.; Liu, Y.; Tian, X.D.; Wang, B. Inhibition of human lung cancer proliferation through targeting stromal fibroblasts by dihydromyricetin. Mol. Cell. Biol. 2017, 37, 9758–9762. [CrossRef]
33. Correa, R.L.; Bruckner, F.P.; de Souza Cascardo, R.; Alfenas-Zerbini, P. The Role of F-Box Proteins during Viral Infection. *Int. J. Mol. Sci.* 2013, 14, 4030–4049. [CrossRef]

34. Ji, S.; Qin, Y.; Shi, S.; Liu, X.; Hu, H.; Zhou, H.; Gao, J.; Zhang, B.; Xu, W.; Liu, J.; et al. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. *Cell Res.* 2015, 25, 561–573. [CrossRef]

35. Chen, X.M.; Xie, X.B.; Zhao, Q.; Wang, F.; Bai, Y.; Yin, J.Q.; Jiang, H.; Xie, X.L.; Jia, Q.; Huang, G. Ampelopsin induces apoptosis by regulating multiple e-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells. *Med. Mol. Biol. Rep.* 2015, 11, 105–112. [CrossRef]

36. George, A.L.; Rajoria, S.; Suriano, R.; Mittleman, A.; Tiwari, R.K. Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence. *Mol. Cancer* 2012, 11, 80. [CrossRef]

37. Zhou, Y.; Shu, F.; Liang, X.; Chang, H.; Shi, L.; Peng, X.; Zou, J.; Mi, M. Ampelopsin induces cell growth inhibition and apoptosis in breast cancer cells through ROS generation and endoplasmic reticulum stress pathway. *PLoS ONE* 2014, 9, e89021. [CrossRef]

38. Li, Y.; Zhou, Y.; Wang, M.; Lin, X.; Zhang, Y.; Laurent, I.; Zhong, Y.; Li, J. Ampelopsin Inhibits Breast Cancer Cell Growth through Mitochondrial Apoptosis Pathway. *Biopharm. Bull.* 2021, 44, 1738–1745. [CrossRef]

39. Li, X.; He, S.; Ma, B. Autophagy and autophagy-related proteins in cancer. *Mol. Cancer* 2020, 19, 12. [CrossRef]

40. Liu, W.; Meng, Y.; Zong, C.; Zhang, S.; Wei, L. Autophagy and Tumorigenesis. *Adv. Exp. Med. Biol.* 2020, 1207, 275–299. [CrossRef]

41. Guo, J.Y.; Xia, B.; White, E. Autophagy-mediated tumor promotion. *Cell 2013*, 155, 1216–1219. [CrossRef][PubMed]

42. Zhou, Y.; Liang, X.; Chang, H.; Shu, F.; Wu, Y.; Zhang, T.; Fu, Y.; Zhang, Q.; Zhu, J.D.; Mi, M. Ampelopsin-induced autophagy protects breast cancer cells from apoptosis through Akt-mTOR pathway via endoplasmic reticulum stress. *Cancer Sci.* 2014, 105, 1279–1287. [CrossRef][PubMed]

43. Biermann, J.S.; Adkins, D.R.; Agulnik, M.; Benjamin, R.S.; Brigman, B.; Butrynski, J.E.; Cheong, D.; Chow, W.; Curry, W.T.; Frassica, D.A.; et al. Bone cancer. *J. Natl. Compr. Cancer Netw.* 2013, 11, 688–723. [CrossRef][PubMed]

44. Wang, Y.; Wang, W.; Qiu, E. Protection of oxidative stress induced apoptosis in osteosarcoma cells by dihydromyricetin through down-regulation of caspase activation and up-regulation of Bcl-2. *Saudi J. Biol. Sci.* 2017, 24, 837–842. [CrossRef][PubMed]

45. Pavon, M.A.; Arroyo-Solera, I.; Cespedes, M.V.; Casanova, I.; Leon, X.; Mangues, R. uPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy. *Oncotarget* 2016, 7, 57351–57366. [CrossRef]

46. Chou, C.H.; Lu, K.H.; Yang, J.S.; Hsieh, Y.H.; Lin, C.W.; Yang, S.F. Dihydmerycetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition. *Phytomed.* 2020, 10, 153642. [CrossRef]

47. Giallesi, C.; Theocharis, A.D.; Karamanos, N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. *FEBS J.* 2011, 278, 16–27. [CrossRef]

48. Liu, C.; Zhao, P.; Yang, Y.; Xu, X.; Wang, L.; Li, B. Ampelopsin suppresses TNF-α-induced migration and invasion of U2OS osteosarcoma cells. *Mol. Med. Rep.* 2016, 13, 4729–4736. [CrossRef]

49. Zhao, Z.; Yin, J.Q.; Wu, M.S.; Song, G.; Xie, X.B.; Zou, C.; Tang, Q.; Wu, Y.; Lu, J.; Wang, Y.; et al. Dihydmerycetin activates AMP-activated protein kinase and P38(MAPK) exerting antitumor potential in osteosarcoma. *Cancer Prev. Res.* 2014, 7, 927–938. [CrossRef]

50. Yokoi, A.; Matsuzaki, J.; Yamamoto, Y.; Yoneoka, Y.; Takahashi, K.; Shimizu, H.; Uehara, T.; Ishikawa, M.; Ikeda, S.I.; Sonoda, T.; et al. Integrated extracellular microRNA profiling for ovarian cancer screening. *Nat. Commun.* 2018, 9, 4319. [CrossRef]

51. Xu, Y.; Wang, S.; Chan, H.F.; Lu, H.; Lin, Z.; He, C.; Chen, M. Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by p53-mediated Downregulation of Survivin. *Sci. Rep.* 2017, 7, 46060. [CrossRef]

52. Nisticò, P.; Bissell, M.J.; Radiasky, D.C. Epithelial-mesenchymal transition: General principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. *Cold Spring Harb. Perspect. Biol.* 2012, 4, a011908. [CrossRef]

53. Parikh, A.; Lee, C.; Joseph, P.; Marchini, S.; Baccarini, A.; Kolev, V.; Romualdi, C.; Fruscio, R.; Shah, H.; Wang, F.; et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. *Nat. Commun.* 2014, 5, 2977. [CrossRef]

54. Liu, T.; Liu, P.; Ding, F.; Yu, N.; Li, S.; Wang, S.; Zhang, X.; Sun, X.; Chen, Y.; Wang, F.; et al. Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition. *Onco. Rep.* 2015, 33, 861–867. [CrossRef]

55. Wang, F.; Chen, X.; Yuan, D.; Yi, Y.; Luo, Y. Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. *PLoS ONE 2019*, 14, e0225450. [CrossRef]

56. Pires, L.V.; Yi, Y.; Cheng, J.C.; Pizzolato, L.S.; Cordero, E.; Leung, P.C.K.; Brum, I.S. Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways. *Anticancer Res.* 2019, 39, 2377–2383. [CrossRef]

57. Pearce, H.; Edwards, D.C.; Levy, J.A.; McGreen, B.H.; Mackovick, L.; Brennan, M.; McHugh, M.; Mapow, B.; Schanne, F.J.; Belkoff, L. Acute pulmonary hemorrhage associated with metastatic testicular choriocarcinoma in a 46-year-old incarcerated male. *Urol. Ann.* 2019, 11, 109–112. [CrossRef]

58. Zuo, Y.; Lu, Y.; Xu, Q.; Sun, D.; Liang, X.; Li, X.; Li, Y. Inhibitory effect of dihydromyricetin on the proliferation of JAR cells and its mechanism of action. *Oncol. Lett.* 2020, 20, 357–363. [CrossRef]

59. Zuo, Y.; Xu, Q.; Lu, Y.; Sun, D.; Wang, K.; Lei, Y.; Liang, X.; Li, Y. Dihydromyricetin induces apoptosis in a human choriocarcinoma cell line. *Oncol. Lett.* 2018, 16, 4229–4234. [CrossRef]
60. Ni, F.; Gong, Y.; Li, L.; Abdolmaleky, H.M.; Zhou, J.R. Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in vivo. *PLoS ONE* **2012**, *7*, e38802. [CrossRef]

61. Zhang, Z.; Zhang, H.; Chen, S.; Xu, Y.; Yao, A.; Liao, Q.; Han, L.; Zou, Z.; Zhang, X. Dihydromyricetin induces mitochondria-mediated apoptosis in HepG2 cells through down-regulation of the Akt/Bad pathway. *Nutr. Res.* **2017**, *38*, 27–33. [CrossRef][PubMed]

62. Liu, J.; Shu, Y.; Zhang, Q.; Liu, B.; Xia, J.; Qiu, M.; Miao, H.; Li, M.; Zhu, R. Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. *Oncol. Lett.* **2014**, *8*, 1645–1651. [CrossRef][PubMed]

63. Zhang, Q.; Liu, J.; Liu, B.; Xia, J.; Chen, N.; Chen, X.; Cao, Y.; Zhang, C.; Lu, C.; Li, M.; et al. Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism. *Sci. Rep.* **2014**, *4*, 4628. [CrossRef][PubMed]

64. Qi, S.; Kou, X.; Lv, J.; Qi, Z.; Yan, L. Ampelopsin induces apoptosis in HepG2 human hepatoma cell line through extrinsic and intrinsic pathways: Involvement of Fas and ERK. *Environ. Toxicol. Pharmacol.* **2015**, *40*, 847–854. [CrossRef][PubMed]

65. Matsuno, K.; Diedrich, R.J.; Go, M.J.; Blaumueller, C.M.; Artavanis-Tsakonas, S. Deltex acts as a positive regulator of Notch signaling through interactions with the Notch ankyrin repeats. *Development* **1995**, *121*, 2633–2644. [CrossRef]

66. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. *Physiol. Rev.* **2007**, *87*, 245–313. [CrossRef]

67. Lu, B.; Zhou, W.; Chen, X.; Xiang, L.J.; Zhang, J.; Liang, Y.R.; Duan, J.; He, Y.H.; Li, M.Y. Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells. *World J. Gastroenterol.* **2017**, *23*, 6242–6251. [CrossRef]

68. Zhang, Q.Y.; Li, R.; Zeng, G.F.; Liu, B.; Liu, J.; Shu, Y.; Liu, Z.K.; Qiu, Z.D.; Wang, D.J.; Miao, H.L.; et al. Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression. *World J. Gastroenterol.* **2014**, *20*, 10082–10093. [CrossRef]

69. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. *Physiol. Rev.* **2007**, *87*, 245–313. [CrossRef]

70. Liu, B.; Zhou, W.; Chen, X.; Xiang, L.J.; Zhang, J.; Liang, Y.R.; Duan, J.; He, Y.H.; Li, M.Y. Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells. *World J. Gastroenterol.* **2017**, *23*, 6242–6251. [CrossRef]

71. Xia, J.; Guo, S.; Fang, T.; Feng, D.; Zhang, X.; Zhang, Q.; Liu, J.; Liu, B.; Li, M.; Zhu, R. Dihydromyricetin induces autophagy in HepG2 cells involved in inhibition of mTOR and regulating its upstream pathways. *Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc.* **2014**, *66*, 7–13. [CrossRef]

72. Wang, F.H.; Shen, L.; Li, J.; Zhou, Z.W.; Liang, H.; Zhang, X.T.; Tang, L.; Xin, Y.; Jin, J.; Zhang, Y.J.; et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer. *Cancer Commun.* **2019**, *39*, 10. [CrossRef]

73. Wei, L.; Sun, J.; Zhang, N.; Zheng, Y.; Wang, X.; Lv, L.; Liu, J.; Xu, Y.; Shen, Y.; Yang, M. Noncoding RNAs in gastric cancer: Implications for drug resistance. *Mol. Cancer* **2020**, *19*, 62. [CrossRef]

74. Ji, F.J.; Tian, X.F.; Liu, X.W.; Fu, L.B.; Wu, Y.Y.; Fang, X.D.; Jin, H.Y. Dihydromyricetin induces cell apoptosis via a p53-related pathway. *Mol. Med. Rep.* **2015**, *11*, 1609–1614. [CrossRef]

75. Xia, J.; Guo, S.; Fang, T.; Feng, D.; Zhang, X.; Zhang, Q.; Liu, J.; Liu, B.; Li, M.; Zhu, R. Dihydromyricetin induces autophagy in HepG2 cells involved in inhibition of mTOR and regulating its upstream pathways. *Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc.* **2014**, *66*, 7–13. [CrossRef]

76. Wang, F.H.; Shen, L.; Li, J.; Zhou, Z.W.; Liang, H.; Zhang, X.T.; Tang, L.; Xin, Y.; Jin, J.; Zhang, Y.J.; et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer. *Cancer Commun.* **2019**, *39*, 10. [CrossRef]

77. Wei, L.; Sun, J.; Zhang, N.; Zheng, Y.; Wang, X.; Lv, L.; Liu, J.; Xu, Y.; Shen, Y.; Yang, M. Noncoding RNAs in gastric cancer: Implications for drug resistance. *Mol. Cancer* **2020**, *19*, 62. [CrossRef]

78. Ji, F.J.; Tian, X.F.; Liu, X.W.; Fu, L.B.; Wu, Y.Y.; Fang, X.D.; Jin, H.Y. Dihydromyricetin induces cell apoptosis via a p53-related pathway in AGS human gastric cancer cells. *Genet. Mol. Res. 2015*, *14*, 15564–15571. [CrossRef]

79. Wang, F.J.; Zong, X.Y.; Du, J.L.; Wang, W.S.; Yuan, D.P.; Chen, X.B. Effects of dihydromyricetin on the migration and invasion of human gastric cancer MKN45 cells and its mechanism. *Zhongguo Yangong Yongsheng Li Xue Za Zhi = Chin. J. Appl. Physiol.* **2019**, *35*, 428–432. [CrossRef]

80. Ohmori, H.; Luo, Y.; Kuniyasu, H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. *Expert Opin. Ther. Targets* **2011**, *15*, 183–193. [CrossRef]

81. Wang, S.; Ge, F.; Cai, T.; Qi, S.; Qi, Z. Dihydromyricetin inhibits proliferation and migration of gastric cancer cells through regulating Akt/STAT3 signaling pathways and HMGB1 expression. *Nat Fang Yi Ke Da Xue Bao = J. South. Med. Univ.* **2021**, *41*, 87–92. [CrossRef]

82. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. *Nat. Rev. Cancer* **2006**, *6*, 857–866. [CrossRef]

83. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. *Nature* **2005**, *435*, 834–838. [CrossRef]

84. Zhan, T.; Zhu, Q.; Han, Z.; Tan, J.; Liu, M.; Liu, W.; Chen, W.; Chen, X.; Chen, X.; Deng, J.; et al. miR-455-3p Functions as a Tumor Suppressor by Restraining Wnt/β-Catenin Signaling via TAZ in Pancreatic Cancer. *Cancer Manag. Res.* **2020**, *12*, 1483–1492. [CrossRef]

85. Yunqi, H.; Fangrui, Y.; Yongyan, Y.; Yunjian, J.; Wenhui, Z.; Kun, C.; Min, L.; Xianfeng, L.; Caixia, B. miR-455 Functions as a Tumor Suppressor Through Targeting GATA6 in Colorectal Cancer. *World J. Gastroenterol.* **2016**, *22*, 490–500. [CrossRef]
85. Zhu, X.H.; Lang, H.D.; Wang, X.L.; Hui, S.C.; Zhou, M.; Kang, C.; Yi, L.; Mi, M.T.; Zhang, Y. Synergy between dihydromyricetin intervention and irinotecan chemotherapy delays the progression of colon cancer in mouse models. *Food Funct.* **2019**, *10*, 2040–2049. [CrossRef]

86. Griffanti, R.; Taranta, M.; Cherantini, D.; Naldi, I.; Parri, M.; Grandi, A.; Giannetti, A.; Tombelli, S.; Lucarini, G.; Ricotti, L.; et al. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. *J. Control. Release Off. J. Control. Release Soc.* **2018**, *280*, 76–86. [CrossRef]

87. Park, G.B.; Jeong, J.Y.; Kim, D. Ampelopsin-induced reactive oxygen species enhance the apoptosis of colon cancer cells by activating endoplasmic reticulum stress-mediated AMPK/MAPK/ERK1 in nasopharyngeal carcinoma cells. *Oncol. Lett.* **2017**, *14*, 7947–7956. [CrossRef] [PubMed]

88. Izano, M.; Wei, E.K.; Tai, C.; Swede, H.; Gregorich, S.; Harris, T.B.; Klepin, H.; Satterfield, S.; Murphy, R.; Newman, A.B.; et al. Chronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study. *Int. J. Cancer* **2016**, *138*, 1118–1218. [CrossRef]

89. Bopanna, S.; Ananthakrishnan, A.N.; Kedia, S.; Yajnik, V.; Ahuja, V. Risk of colorectal cancer in Asian patients with ulcerative colitis: A systematic review and meta-analysis. *Lancet Gastroenterol. Hepatol.* **2017**, *2*, 269–276. [CrossRef]

90. Clarke, W.T.; Feuerstein, J.D. Updates in colorectal cancer screening in inflammatory bowel disease. *Curr. Opin. Gastroenterol.* **2018**, *34*, 208–216. [CrossRef]

91. Liu, Y.; Hou, Y.; Ma, L.; Sun, C.; Pan, J.; Yang, Y.; Zhou, H.; Zhang, J. Regulation of semaphorin 4D expression and cell proliferation of ovarian cancer by ERalpha and ERbeta. *Braz. J. Med. Biol. Res. = Rev. Bras. Pesqui. Med. E Biol.* **2017**, *50*, e6057. [CrossRef] [PubMed]

92. Ding, X.; Qiu, L.; Zhang, L.; Xi, J.; Li, D.; Huang, X.; Zhao, Y.; Wang, X.; Sun, Q. The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer. *OncoTargets Ther.* **2016**, *9*, 1189–1204. [CrossRef]

93. Liang, J.; Wu, J.; Wang, F.; Zhang, Z.; Zhang, X. Semaphoring 4D is required for the induction of antioxidant stress and anti-inflammatory effects of dihydromyricetin in colon cancer. *Int. Immunopharmacol.* **2019**, *67*, 220–230. [CrossRef]

94. Pietrobono, S.; Anichini, G.; Sala, C.; Manetti, F.; Almada, L.L.; Pepe, S.; Carr, R.M.; Paradise, B.D.; Sarkaria, J.N.; Davila, J.I.; et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AKL. *Nat. Commun.* **2020**, *11*, 5865. [CrossRef]

95. Zeng, G.; Liu, J.; Chen, H.; Liu, B.; Zhang, Q.; Li, M.; Zhu, R. Dihydromyricetin induces cell cycle arrest and apoptosis in melanoma SK-MEL-28 cells. *Oncol. Rep.* **2014**, *31*, 2713–2719. [CrossRef]

96. Zhou, D.Z.; Sun, H.Y.; Yue, J.Q.; Peng, Y.; Chen, Y.M.; Zhong, Z.J. Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NFκB signalling in human melanoma cells. *Free Radic. Res.* **2017**, *51*, 517–528. [CrossRef]

97. Zheng, H.Q.; Liu, D.Y. Anti-invasive and anti-metastatic effect of ampelopsin on melanoma. *Ai Zheng = Aizheng = Chin. J. Cancer* **2003**, *22*, 363–367.

98. Mosca, L.; Minopoli, M.; Pagano, M.; Vitiello, F.; Carriero, M.V.; Cacciapuoti, G.; Porcelli, M. Effects of S-adenosyl-L-methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms. *Int. J. Oncol.* **2020**, *56*, 1212–1224. [CrossRef]

99. Fan, T.F.; Wu, T.F.; Bu, L.L.; Ma, S.R.; Li, Y.C.; Mao, L.; Sun, Z.J.; Zhang, W.F. Dihydromyricetin promotes autophagy and apoptosis through ROS-STAT3 signal in colorectal cancer cells. *Oncotarget* **2016**, *7*, 59691–59703. [CrossRef]

100. Sun, L.; Sun, P.; Zhou, Q.Y.; Gao, X.; Han, Q. Long noncoding RNA MALAT1 promotesveal melanoma cell growth and invasion by silencing of miR-140. *Am. J. Transl. Res.* **2016**, *8*, 3939–3946. [CrossRef]

101. Liu, J.; Peng, W.X.; Mo, Y.Y.; Luo, D. MALAT1-mediated tumorigenesis. *Front. Biosci.* **2017**, *22*, 66–80. [CrossRef]

102. Tan, M.; Jiang, B.; Wang, H.; Ouyang, W.; Chen, X.; Wang, T.; Dong, D.; Yi, S.; Yi, J.; Huang, Y.; et al. Dihydromyricetin induced IncRNA MALAT1-TFEB-dependent autophagic cell death in cutaneous squamous cell carcinoma. *J. Cancer* **2019**, *10*, 4245–4255. [CrossRef]

103. Abdullah, B.; Alias, A.; Hassan, S. Challenges in the management of nasopharyngeal carcinoma: A review. *Malays. J. Med. Sci.* **2009**, *16*, 50–54.

104. Li, C.H.; Ding, H.; Shi, J.L.; Huang, B.; Ding, H.; Lin, H.G.; Zeng, J.C.; Zhao, Y.; Luo, G.Q. Dihydromyricetin promotes apoptosis, suppresses proliferation and tumor necrosis factor-a-mediated nuclear factor kappa-B activation in nasopharyngeal carcinoma CNE-2 cell. *J. Tradit. Chin. Med. = Chung I Ta Chih Ying Wen Pan* **2021**, *41*, 367–375. [CrossRef]

105. Chen, Z.; Shi, T.; Zhang, L.; Zhu, P.; Deng, M.; Huang, C.; Hu, T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. *Cancer Lett.* **2016**, *370*, 153–164. [CrossRef]

106. Yan, L.H.; Wei, W.Y.; Cao, W.L.; Zhang, X.S.; Xie, Y.B.; Xiao, Q. Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance. *Am. J. Cancer Res.* **2015**, *5*, 321–332.
109. Theodoulou, M.; Hudis, C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004, 100, 2052–2063. [CrossRef]

110. Zhu, H.; Luo, P.; Fu, Y.; Wang, J.; Dai, J.; Shao, J.; Yang, X.; Chang, L.; Weng, Q.; Yang, B.; et al. Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by Adriamycin. Oncotarget 2015, 6, 3254–3267. [CrossRef]

111. Sun, Y.; Liu, W.; Wang, C.; Meng, Q.; Liu, Z.; Huo, X.; Yang, X.; Sun, P.; Sun, H.; Ma, X.; et al. Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of Adriamycin in K562/ADR through downregulation of MDR1: A new strategy of inhibiting P-glycoprotein. J. Cell. Physiol. 2019, 234, 3685–3696. [CrossRef] [PubMed]

112. Ye, J.; Zheng, Y.; Liu, D. Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells. Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China J. Chin. Mater. Med. 2009, 34, 761–765.

113. Wu, M.; Jiang, M.; Dong, T.; Xu, L.; Lv, J.; Xue, M.; Huang, M. Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells. Asian Pac. J. Cancer Prev. 2020, 21, 1269–1274. [CrossRef] [PubMed]

114. Altieri, D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3, 46–54. [CrossRef] [PubMed]

115. Hong, S.W.; Park, N.S.; Noh, M.H.; Shim, J.A.; Ahn, B.N.; Kim, Y.S.; Kim, D.; Lee, H.K.; Hur, D.Y. Combination Treatment with Erlotinib and Ampelopsin Overcomes Erlotinib Resistance in NSCLC Cells via the Nox2-ROS-Bim Pathway. Lung Cancer 2017, 106, 115–124. [CrossRef] [PubMed]

116. Jiang, L.; Zhang, Q.; Ren, H.; Ma, S.; Lu, C.; Liu, B.; Jiang, J.; Li, M.; Zhu, R. Dihydromyricetin Enhances the Chemosensitivity of Nodal Involvement via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. PLoS ONE 2015, 10, e0124994. [CrossRef] [PubMed]

117. Wang, Z.; Sun, X.; Feng, Y.; Liu, X.; Zhou, L.; Sui, H.; Ji, Q.; Chen, J.; Wu, L.; Li, Q. Dihydromyricetin Reverses MR2-mediated MDR and Enhances Anticancer Activity Induced by Oxpaliplatin in Cerebral Cancer Cells. Anti-Cancer Drugs 2017, 28, 281–288. [CrossRef]

118. Wang, Z.; Sun, X.; Feng, Y.; Wang, Y.; Zhang, L.; Wang, Y.; Fang, Z.; Azami, N.L.B.; Sun, M.; Li, Q. Dihydromyricetin Reverses MR2-Induced Multidrug Resistance by Preventing NF-kB-Nrf2 Signaling in Cerebral Cancer Cells. Phytochem. Int. J. Phytother. Phytophar. 2021, 82, 153414. [CrossRef]

119. Ruan, L.P.; Yu, B.Y.; Fu, G.M.; Zhu, D.N. Improving the Solubility of Ampelopsin by Solid Dispersions and Inclusion Complexes. J. Pharm. Biomed. Anal. 2005, 38, 457–464. [CrossRef]

120. Chen, L.; Shi, M.; Lv, C.; Song, Y.; Wu, Y.; Liu, S.; Zheng, Z.; Lu, X.; Qin, S. Dihydromyricetin Acts as a Potential Redox Balance Mediator in Cancer Chemoprevention. Mediat. Inflamm. 2021, 2021, 6692579. [CrossRef]

121. Xiang, D.; Wang, C.G.; Wang, W.Q.; Shi, C.Y.; Xiong, W.; Wang, M.D.; Fang, J.G. Gastrointestinal Stability of Dihydromyricetin, myricetin, and myricitrin: An in vivo investigation. Int. J. Food. Nutr. 2017, 68, 704–711. [CrossRef]

122. Abuhelwa, A.Y.; Foster, D.J.R.; Upton, R.N. A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption-Part I: Gastrointestinal pH. AAPS J. 2016, 18, 1309–1321. [CrossRef]

123. Tong, Q.; Hou, X.; Fang, J.; Wang, W.; Xiong, W.; Liu, X.; Xie, X.; Shi, C. Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. J. Pharm. Biomed. Anal. 2015, 114, 455–461. [CrossRef]

124. Xiang, D.; Fan, L.; Hou, X.L.; Xiong, W.; Shi, C.Y.; Wang, W.Q.; Fang, J.G. Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco-2 Cells. J. Food Sci. 2018, 83, 1941–1947. [CrossRef]

125. Yun, C.W.; Lee, S.H. The Roles of Autophagy in Cancer. Int. J. Mol. Sci. 2018, 19, 3466. [CrossRef]

126. Kenifíc, C.M.; Deb Nath, J. Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol. 2015, 25, 37–45. [CrossRef]

127. Dikic, I.; Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 2018, 19, 349–364. [CrossRef]

128. Chebil, L.; Humeau, C.; Falcimaigne, A.; Engasser, J.-M.; Ghoul, M. Enzymatic acylation of flavonoids. Process Biochem. 2006, 41, 2237–2251. [CrossRef]

129. Li, W.; Wu, H.; Liu, B.; Hou, X.; Wan, D.; Lou, W.; Zhao, J. Highly efficient and regioselective synthesis of dihydromyricetin esters by immobilized lipase. J. Biotechnol. 2015, 199, 31–37. [CrossRef]

130. Cao, S.L.; Deng, X.; Xu, P.; Huang, Z.X.; Zhou, J.; Li, X.H.; Zong, M.H.; Lou, W.Y. Highly Efficient Enzymatic Acylation of Dihydromyricetin by the Immobilized Lipase with Deep Eutectic Solvents as Cosolvent. J. Agric. Food Chem. 2017, 65, 2084–2088. [CrossRef]

131. Guo, Q.Q.; Zeng, J.H.; Lu, Y.; Shu, X.G. Effects of Solubility, Thermal Stability and Antioxidant Properties of Acylating Dihydromyricetin. Adv. Mater. Res. 2010, 79–81, 101–105. [CrossRef]

132. Plaza, M.; Pozzo, T.; Liu, J.; Gulshan Ara, K.Z.; Turner, C.; Nordberg Karlsson, E. Substituent effects on in vitro antioxidizing properties, stability, and solubility in flavonoids. J. Agric. Food Chem. 2014, 62, 3321–3333. [CrossRef]

133. Lee, Y.S.; Woo, J.B.; Ryu, S.I.; Moon, S.K.; Han, N.S.; Lee, S.B. Glucosylation of flavonol and flavanones by Bacillus cyclodehydrin glucosyltransferase to enhance their solubility and stability. J. Pharm. Biomed. Anal. 2017, 129, 75–83. [CrossRef]

134. Woo, H.J.; Kang, H.K.; Nguyen, T.T.; Kim, G.E.; Kim, Y.M.; Park, J.S.; Kim, D.; Cha, J.; Moon, Y.H.; Nam, S.H.; et al. Synthesis and characterization of ampelopsin glucosides using dextran transuse from Leuconostoc mesenteroides B-1299CB4: Glucosylation enhancing physicochemical properties. Enzym. Microb. Technol. 2012, 51, 311–318. [CrossRef]

135. Zhang, J.; Brodbelt, J.S.; Wang, J. Threshold dissociation and molecular modeling of transition metal complexes of flavonoids. J. Am. Soc. Mass Spectrom. 2005, 16, 139–151. [CrossRef]
136. Samsonowicz, M.; Regulska, E. Spectroscopic study of molecular structure, antioxidant activity and biological effects of metal hydroxyflavonol complexes. *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* **2017**, *173*, 757–771. [CrossRef]

137. Guo, Q.; Yuan, J.; Zeng, J. Binding of dihydromyricetin and its metal ion complexes with bovine serum albumin. *Biotechnol. Biotechnol. Equip.* **2014**, *28*, 333–341. [CrossRef]

138. Bilia, A.R.; Piazzini, V.; Guccione, C.; Risaliti, L.; Aspreea, M.; Capecchi, G.; Bergonzi, M.C. Improving on Nature: The Role of Nanomedicine in the Development of Clinical Natural Drugs. *Planta Med.* **2017**, *83*, 366–381. [CrossRef]

139. Ye, J.; Bao, S.; Zhao, S.; Zhu, Y.; Ren, Q.; Li, R.; Xu, X.; Zhang, Q. Self-Assembled Micelles Improve the Oral Bioavailability of Dihydromyricetin and Anti-Acute Alcoholism Activity. *AAPS PharmSciTech* **2021**, *22*, 111. [CrossRef] [PubMed]

140. Luo, F.; Zeng, D.; Chen, R.; Zafar, A.; Weng, L.; Wang, W.; Tian, Y.; Hasan, M.; Shu, X. PEGylated dihydromyricetin-loaded nanoliposomes coated with tea saponin inhibit bacterial oxidative respiration and energy metabolism. *Food Funct.* **2021**, *12*, 9007–9017. [CrossRef] [PubMed]

141. Sun, C.C.; Su, H.; Zheng, G.D.; Wang, W.J.; Yuan, E.; Zhang, Q.F. Fabrication and characterization of dihydromyricetin encapsulated zein-caseinate nanoparticles and its bioavailability in rat. *Food Chem.* **2020**, *330*, 127245. [CrossRef] [PubMed]

142. Patel, A.; Hu, Y.; Tiwari, J.K.; Velikov, K.P. Synthesis and characterisation of zein-curcumin colloidal particles. *Soft Matter* **2010**, *6*, 6192–6199. [CrossRef]

143. Gascon, N.; Almansa, C.; Merlos, M.; Miguel Vela, J.; Encina, G.; Morte, A.; Smith, K.; Plata-Salamán, C. Co-crystal of tramadol-celecoxib: Preclinical and clinical evaluation of a novel analgesic. *Expert Opin. Investig. Drugs* **2019**, *28*, 399–409. [CrossRef]

144. Shinozaki, T.; Ono, M.; Higashi, K.; Moribe, K. A Novel Drug-Drug Cocrystal of Levofloxacin and Metacamol: Reduced Hygroscopicity and Improved Photostability of Levofloxacin. *J. Pharm. Sci.* **2019**, *108*, 2383–2390. [CrossRef]

145. Liu, L.; Li, Y.; Zhang, M.; Zhang, Y.; Lou, B. A Drug-Drug Cocrystal of Dihydromyricetin and Pentoxifylline. *J. Pharm. Sci.* **2022**, *111*, 82–87. [CrossRef]

146. Liu, H.; Zhao, W.; Hu, Q.; Zhao, L.; Wei, Y.; Pi, C.; Yang, Y.; Yang, X.; Yuan, H.; Zhang, Y.; et al. Gastric floating sustained-release tablet for dihydromyricetin: Development, characterization, and pharmacokinetics study. *Saudi Pharm. J.* **2019**, *27*, 1000–1008. [CrossRef]

147. Liu, B.; Tan, X.; Liang, J.; Wu, S.; Liu, J.; Zhang, Q.; Zhu, R. A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells. *Sci. Rep.* **2014**, *4*, 7041. [CrossRef]